vs
Side-by-side financial comparison of Apyx Medical Corp (APYX) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
Apyx Medical Corp is the larger business by last-quarter revenue ($19.2M vs $12.5M, roughly 1.5× SOLESENCE, INC.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -6.8%, a 8.1% gap on every dollar of revenue. On growth, Apyx Medical Corp posted the faster year-over-year revenue change (34.7% vs -0.7%). Over the past eight quarters, Apyx Medical Corp's revenue compounded faster (36.8% CAGR vs 12.5%).
Bovie Medical Corporation was an American medical device manufacturer of medical devices, electrosurgical products and energy technologies. It was based in Clearwater, Florida with a manufacturing facility in Bulgaria.
APYX vs SLSN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.2M | $12.5M |
| Net Profit | $-1.3M | $163.0K |
| Gross Margin | 62.6% | 27.5% |
| Operating Margin | 0.1% | 1.5% |
| Net Margin | -6.8% | 1.3% |
| Revenue YoY | 34.7% | -0.7% |
| Net Profit YoY | 71.9% | 129.2% |
| EPS (diluted) | — | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $19.2M | $12.5M | ||
| Q3 25 | $12.9M | $14.6M | ||
| Q2 25 | $11.4M | $20.4M | ||
| Q1 25 | $9.4M | $14.6M | ||
| Q4 24 | $14.2M | $12.6M | ||
| Q3 24 | $11.5M | $16.9M | ||
| Q2 24 | $12.1M | $13.0M | ||
| Q1 24 | $10.2M | $9.9M |
| Q4 25 | $-1.3M | $163.0K | ||
| Q3 25 | $-2.0M | $-1.1M | ||
| Q2 25 | $-3.8M | $2.7M | ||
| Q1 25 | $-4.2M | $80.0K | ||
| Q4 24 | $-4.6M | $-559.0K | ||
| Q3 24 | $-4.7M | $3.0M | ||
| Q2 24 | $-6.6M | $856.0K | ||
| Q1 24 | $-7.6M | $893.0K |
| Q4 25 | 62.6% | 27.5% | ||
| Q3 25 | 64.4% | 23.1% | ||
| Q2 25 | 62.3% | 28.9% | ||
| Q1 25 | 60.1% | 23.1% | ||
| Q4 24 | 63.0% | 22.0% | ||
| Q3 24 | 60.5% | 36.2% | ||
| Q2 24 | 61.7% | 28.7% | ||
| Q1 24 | 58.1% | 36.3% |
| Q4 25 | 0.1% | 1.5% | ||
| Q3 25 | -6.5% | -5.4% | ||
| Q2 25 | -22.6% | 9.4% | ||
| Q1 25 | -32.4% | 1.8% | ||
| Q4 24 | -21.4% | -1.8% | ||
| Q3 24 | -31.6% | 19.0% | ||
| Q2 24 | -45.7% | 8.0% | ||
| Q1 24 | -64.6% | 11.3% |
| Q4 25 | -6.8% | 1.3% | ||
| Q3 25 | -15.4% | -7.7% | ||
| Q2 25 | -33.2% | 13.1% | ||
| Q1 25 | -44.0% | 0.5% | ||
| Q4 24 | -32.5% | -4.4% | ||
| Q3 24 | -40.9% | 18.1% | ||
| Q2 24 | -54.0% | 6.6% | ||
| Q1 24 | -74.0% | 9.0% |
| Q4 25 | — | $0.00 | ||
| Q3 25 | — | $-0.02 | ||
| Q2 25 | — | $0.04 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $0.00 | ||
| Q3 24 | — | $0.04 | ||
| Q2 24 | $-0.19 | $0.01 | ||
| Q1 24 | $-0.22 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.7M | $1.3M |
| Total DebtLower is stronger | $37.5M | — |
| Stockholders' EquityBook value | $14.5M | $17.6M |
| Total Assets | $66.8M | $50.1M |
| Debt / EquityLower = less leverage | 2.58× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.7M | $1.3M | ||
| Q3 25 | $25.1M | $429.0K | ||
| Q2 25 | $29.3M | $4.1M | ||
| Q1 25 | $31.0M | $1.8M | ||
| Q4 24 | $31.7M | $1.4M | ||
| Q3 24 | $28.0M | $2.9M | ||
| Q2 24 | $32.7M | $2.4M | ||
| Q1 24 | $37.3M | $2.0M |
| Q4 25 | $37.5M | — | ||
| Q3 25 | $37.5M | — | ||
| Q2 25 | $37.5M | — | ||
| Q1 25 | $37.5M | — | ||
| Q4 24 | $37.5M | — | ||
| Q3 24 | $37.5M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $14.5M | $17.6M | ||
| Q3 25 | $5.8M | $17.2M | ||
| Q2 25 | $7.3M | $18.2M | ||
| Q1 25 | $10.5M | $15.2M | ||
| Q4 24 | $14.2M | $14.9M | ||
| Q3 24 | $11.0M | $15.2M | ||
| Q2 24 | $14.7M | $11.9M | ||
| Q1 24 | $20.3M | $5.0M |
| Q4 25 | $66.8M | $50.1M | ||
| Q3 25 | $57.4M | $54.0M | ||
| Q2 25 | $58.2M | $60.0M | ||
| Q1 25 | $60.2M | $57.0M | ||
| Q4 24 | $64.8M | $50.0M | ||
| Q3 24 | $60.7M | $48.0M | ||
| Q2 24 | $65.4M | $40.8M | ||
| Q1 24 | $70.7M | $38.5M |
| Q4 25 | 2.58× | — | ||
| Q3 25 | 6.41× | — | ||
| Q2 25 | 5.17× | — | ||
| Q1 25 | 3.57× | — | ||
| Q4 24 | 2.64× | — | ||
| Q3 24 | 3.40× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.5M | $1.8M |
| Free Cash FlowOCF − Capex | $-2.8M | — |
| FCF MarginFCF / Revenue | -14.6% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | — | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | $-9.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.5M | $1.8M | ||
| Q3 25 | $-3.5M | $-2.5M | ||
| Q2 25 | $-1.2M | $-654.0K | ||
| Q1 25 | $-702.0K | $-7.2M | ||
| Q4 24 | $-2.9M | $2.2M | ||
| Q3 24 | $-4.4M | $4.2M | ||
| Q2 24 | $-4.3M | $-565.0K | ||
| Q1 24 | $-6.3M | $-3.9M |
| Q4 25 | $-2.8M | — | ||
| Q3 25 | $-4.1M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-757.0K | — | ||
| Q4 24 | $-3.2M | $-404.0K | ||
| Q3 24 | $-4.6M | $2.8M | ||
| Q2 24 | $-4.6M | $-1.0M | ||
| Q1 24 | $-6.4M | $-3.9M |
| Q4 25 | -14.6% | — | ||
| Q3 25 | -31.5% | — | ||
| Q2 25 | -13.2% | — | ||
| Q1 25 | -8.0% | — | ||
| Q4 24 | -22.4% | -3.2% | ||
| Q3 24 | -40.0% | 16.6% | ||
| Q2 24 | -38.0% | -8.0% | ||
| Q1 24 | -62.2% | -39.9% |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 2.3% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 1.7% | 20.6% | ||
| Q3 24 | 1.3% | 8.3% | ||
| Q2 24 | 2.4% | 3.7% | ||
| Q1 24 | 0.3% | 0.9% |
| Q4 25 | — | 11.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.25× | ||
| Q1 25 | — | -90.26× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.38× | ||
| Q2 24 | — | -0.66× | ||
| Q1 24 | — | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
